TOURMALINE BIO INC. - COMMON STOCK

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

02 май 2025 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

13 мар 2025 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

03 мар 2025 07:15:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

27 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

10 янв 2025 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

10 дек 2024 08:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

14 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

07 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

15 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

11 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

08 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

03 сен 2024 07:45:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

08 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

02 авг 2024 16:30:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

27 июн 2024 08:05:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

23 май 2024 07:10:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

16 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

13 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

19 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire